CDMOs offering Process Development with mRNA
28 published
28 published CDMOs match Process Development and mRNA.
Locations in this set include United States, Spain, United Kingdom, Canada, China, and Denmark.
Capabilities that show up most often in this set: CMC Analytical Development, mRNA Manufacturing, Technology Transfer, Quality Control Testing, and CMC Regulatory Submission Support.
Matching companies
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Sophia CDMOEuropean CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.
Symbiosis Pharmaceutical ServicesUK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TriLink BioTechnologiesTriLink manufactures mRNA, oligonucleotides, and modified nucleotides with proprietary CleanCap® capping technology achieving >95% Cap1 efficiency, supported by in-house analytical method development and a 118,000 sq ft GMP-capable facility.
Vernal BiosciencesVernal Biosciences is a leading mRNA CDMO providing high-purity mRNA, LNP formulation, process development, GMP manufacturing, and analytical testing for vaccines, gene therapies, and mRNA therapeutics.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
eXmoor PharmaIntegrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.
Markdown mirror: /explore/process-development/mrna.md